Advancing Asthma Care: A Proactive Approach to a Chronic Lung Disease

Asthma is a prevalent, chronic, and manageable lung disease impacting a significant portion of the U.S. population, incurring an estimated US$82 billion annually in healthcare costs. Michigan, in particular, experiences higher adult asthma rates at approximately 12% compared to the 9% national average.

Detroit ranks as the city with the highest asthma burden in the U.S., evidenced by prevalence, emergency department visits, and fatalities. Between 2021 and 2023, Detroit's adult asthma rate was 14.8%, with childhood asthma nearly doubling the state average. Hospitalizations for asthma in Detroit also surpassed state averages from 2019 to 2023, disproportionately affecting Black residents, women, and individuals with lower incomes.

Personalized Care Advances

Asthma specialists are incorporating personalized care plans, emphasizing patient reflection on their disease journey. This approach addresses patient denial about chronic conditions and examines the long-term effects of treatments like corticosteroids or frequent emergency department visits.

This personalized understanding forms the basis for implementing advanced scientific therapies, with ongoing clinical trials at institutions like the University of Michigan exploring novel treatments and proactive care strategies.

Personalized care also allows for discussion of related health issues, such as the challenges patients face with weight management due to asthma symptoms or steroid side effects.

Limitations of Reactive Care

Research indicates that asthma is a heterogeneous syndrome, manifesting differently across individuals. While some experience mild, manageable asthma, others face a lifelong struggle with frequent flare-ups, hospitalizations, and declining lung function. Even individuals with "mild" asthma can experience severe, acute episodes.

Most patients typically seek medical attention only when symptoms become severe, often involving overuse of rescue inhalers or urgent care visits. Frequent exacerbations increase the risk of future flare-ups, lung function loss, and mortality. Oral steroids, commonly used to treat flare-ups, carry risks such as osteoporosis, diabetes, or cardiovascular disease with as few as two courses per year. Poorly controlled asthma can also lead to irreversible airway damage.

Emergency departments are frequently used for asthma care due to factors like limited knowledge, high medication costs, and access barriers, despite not being equipped for comprehensive, long-term asthma management.

The current healthcare model is often reactive, addressing symptoms after they escalate rather than proactively managing risk.

Tailored Interventions and Early Detection

A more effective approach involves recognizing asthma's variability and moving beyond "one-size-fits-all" care. Allergen control, for example, requires multifaceted strategies tailored to specific triggers and patient sensitivities, rather than isolated interventions. Conversely, allergen control is often ineffective and costly for individuals without clear sensitivities.

Effective care is established through patient-clinician dialogue, trigger testing, and evidence-based interventions customized for each individual. Many patients also underestimate their asthma severity or overestimate their control.

Red flags, such as daytime symptoms more than twice weekly, nighttime symptoms more than twice monthly, frequent inhaler use, or limited physical activity, signal increased risk. These indicators can be managed in approximately 95% of patients through minimal medications, proper inhaler technique, environmental trigger management, and treatment of coexisting conditions. For the 5% to 10% with severe or hard-to-treat asthma, specialist care and close monitoring are crucial, addressing factors like long-term steroid use, inhaler technique, lifestyle, and coexisting conditions.

New Diagnostic Tools and Therapies

Emerging tools, including blood and breath tests, can assess airway inflammation and predict flare-ups, treatment failures, or lung function decline. These tools represent a significant step toward proactive care by identifying issues before severe impacts occur. Patients exhibiting inflammation markers in both blood and breath tests face a higher risk of future lung function loss and exacerbations.

Targeted therapies known as biologics are another major advancement. These injectable medications, often self-administered, control asthma-related inflammation.

In appropriate patients, biologics can reduce flare-ups and hospitalizations, improve lung function and quality of life, and decrease reliance on oral steroids. While many insurance programs cover certain biologics, actual approval and out-of-pocket costs can vary.